Erratum to "Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome" [Neurosci. Lett., 591 (2015) 86-92], doi: 10.1016/j.neulet.2015.02.008;Chronic P7C3 treatment restores hippocampal neurogenesis

Neuroscience Letters

Volumn 591, Issue , 2015, Pages 86-92

  Latchney, Sarah E ^a   Jaramillo, Thomas C ^b   Rivera, Phillip D ^a   Eisch, Amelia J ^a   Powell, Craig M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AC3; BrdU; Dentate gyrus; Doublecortin; Ki67; Neuronal survival

Indexed keywords

AMINOPROPYL CARBAZOLE P7C3; BROXURIDINE; CARBAZOLE DERIVATIVE; CASPASE 3; MONOCLONAL ANTIBODY KI 67; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; P7C3 COMPOUND;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CELL COUNT; CELL SURVIVAL; CELL VOLUME; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DENTATE GYRUS; DOWN SYNDROME; FEMALE; GRANULE CELL; HIPPOCAMPUS; MALE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY;

ANIMALS; CARBAZOLES; DOWN SYNDROME; FEMALE; HIPPOCAMPUS; MALE; MICE; NEUROGENESIS; NEUROPROTECTIVE AGENTS;

EID: 84923013532     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.04.024     Document Type: Erratum

References (40)

1. Best T.K., Cramer N.P., Chakrabarti L., Haydar T.F., Galdzicki Z. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp. Neurol. 2012, 233:749-757.
2. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010, 20:106-118.
3. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
4. Blaya M.O., Bramlett H., Nadoo J., Pieper A.A., Dietrich W.D. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J. Neurotrauma 2013, 31.
5. Brown J.P., Couillard-Despres S., Cooper-Kuhn C.M., Winkler J., Aigner L., Kuhn H.G. Transient expression of doublecortin during adult neurogenesis. J. Comp. Neurol. 2003, 467:1-10.
6. Busciglio J., Pelsman A., Helguera P., Ashur-Fabian O., Pinhasov A., Brenneman D.E., Gozes I. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharm. Des. 2007, 13:1091-1098.
7. Chakrabarti L., Best T.K., Cramer N.P., Carney R.S., Isaac J.T., Galdzicki Z., Haydar T.F. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 2010, 13:927-934.
8. Chakrabarti L., Galdzicki Z., Haydar T.F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 2007, 27:11483-11495.
9. Chakrabarti L., Scafidi J., Gallo V., Haydar T.F. Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome. Dev. Neurosci. 2011, 33:428-441.
10. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
11. Contestabile A., Benfenati F., Gasparini L. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol. 2010, 91:1-22.
12. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
13. Contestabile A., Greco B., Ghezzi D., Tucci V., Benfenati F., Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest. 2013, 123:348-361.
14. Dang V., Medina B., Das D., Moghadam S., Martin K.J., Lin B., Naik P., Patel D., Nosheny R., Wesson Ashford J., Salehi A. Formoterol, a long-acting beta2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol. Psychiatry 2013, 75.
15. De Jesus-Cortes H., Xu P., Drawbridge J., Estill S.J., Huntington P., Tran S., Britt J., Tesla R., Morlock L., Naidoo J., Melito L.M., Wang G., Williams N.S., Ready J.M., McKnight S.L., Pieper A.A. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17010-17015.
16. Gage F.H., Thompson R.G. Differential distribution of norepinephrine and serotonin along the dorsal-ventral axis of the hippocampal formation. Brain Res. Bull. 1980, 5:771-773.
17. Gotti S., Caricati E., Panzica G. Alterations of brain circuits in Down syndrome murine models. J. Chem. Neuroanat. 2011, 42:317-326.
18. Guidi S., Bonasoni P., Ceccarelli C., Santini D., Gualtieri F., Ciani E., Bartesaghi R. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 2008, 18:180-197.
19. Guidi S., Stagni F., Bianchi P., Ciani E., Ragazzi E., Trazzi S., Grossi G., Mangano C., Calza L., Bartesaghi R. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol. 2013, 23:129-143.
20. Jinno S., Kosaka T. Patterns of expression of neuropeptides in GABAergic nonprincipal neurons in the mouse hippocampus: quantitative analysis with optical disector. J. Comp. Neurol. 2003, 461:333-349.
21. Kee N., Sivalingam S., Boonstra R., Wojtowicz J.M. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J. Neurosci. Methods 2002, 115:97-105.
22. Kempermann G., Jessberger S., Steiner B., Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 2004, 27:447-452.
23. Kurt M.A., Kafa M.I., Dierssen M., Davies D.C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004, 1022:101-109.
24. Latchney S.E., Masiulis I., Zaccaria K.J., Lagace D.C., Powell C.M., McCasland J.S., Eisch A.J. Developmental and adult GAP-43 deficiency in mice dynamically alters hippocampal neurogenesis and mossy fiber volume. Dev. Neurosci. 2014, 36:44-63.
25. Latchney S.E., Rivera P.D., Mao X.W., Ferguson V.L., Bateman T.A., Stodieck L.S., Nelson G.A., Eisch A.J. The effect of spaceflight on mouse olfactory bulb volume, neurogenesis, and cell death indicates the protective effect of novel environment. J. Appl. Physiol. (1985) 2014, 116:1593-1604.
26. Llorens-Martin M.V., Rueda N., Tejeda G.S., Florez J., Trejo J.L., Martinez-Cue C. Effects of voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a model of Down syndrome. Neuroscience 2010, 171:1228-1240.
27. Lu J., Esposito G., Scuderi C., Steardo L., Delli-Bovi L.C., Hecht J.L., Dickinson B.C., Chang C.J., Mori T., Sheen V. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS ONE 2011, 6:e22126.
28. Lu J., Lian G., Zhou H., Esposito G., Steardo L., Delli-Bovi L.C., Hecht J.L., Lu Q.R., Sheen V. OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors. Hum. Mol. Genet. 2012, 21:2330-2340.
29. Martinez-Cue C., Martinez P., Rueda N., Vidal R., Garcia S., Vidal V., Corrales A., Montero J.A., Pazos A., Florez J., Gasser R., Thomas A.W., Honer M., Knoflach F., Trejo J.L., Wettstein J.G., Hernandez M.C. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 2013, 33:3953-3966.
30. Pieper A.A., Xie S., Capota E., Estill S.J., Zhong J., Long J.M., Becker G.L., Huntington P., Goldman S.E., Shen C.H., Capota M., Britt J.K., Kotti T., Ure K., Brat D.J., Williams N.S., MacMillan K.S., Naidoo J., Melito L., Hsieh J., De Brabander J., Ready J.M., McKnight S.L. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010, 142:39-51.
31. Roubertoux P.L., Carlier M. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome). Am. J. Med. Genet. Semin. Med. Genet. 2010, 154C:400-416.
32. Schmidt-Sidor B., Wisniewski K.E., Shepard T.H., Sersen E.A. Brain growth in Down syndrome subjects 15-22 weeks of gestational age and birth to 60 months. Clin. Neuropathol. 1990, 9:181-190.
33. Stagni F., Magistretti J., Guidi S., Ciani E., Mangano C., Calza L., Bartesaghi R. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome. PLoS ONE 2013, 8:e61689.
34. Sylvester P.E. The hippocampus in Down's syndrome. J. Ment. Defic. Res. 1983, 27(Pt 3):227-236.
35. Tesla R., Wolf H.P., Xu P., Drawbridge J., Estill S.J., Huntington P., McDaniel L., Knobbe W., Burket A., Tran S., Starwalt R., Morlock L., Naidoo J., Williams N.S., Ready J.M., McKnight S.L., Pieper A.A. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17016-17021.
36. Toso L., Cameroni I., Roberson R., Abebe D., Bissell S., Spong C.Y. Prevention of developmental delays in a Down syndrome mouse model. Obstet. Gynecol. 2008, 112:1242-1251.
37. Velazquez R., Ash J.A., Powers B.E., Kelley C.M., Strawderman M., Luscher Z.I., Ginsberg S.D., Mufson E.J., Strupp B.J. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2013, 58C:92-101.
38. Walker A.K., Rivera P.D., Wang Q., Chuang J.C., Tran S., Osborne-Lawrence S., Estill S.J., Starwalt R., Huntington P., Morlock L., Naidoo J., Williams N.S., Ready J.M., Eisch A.J., Pieper A.A., Zigman J.M. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol. Psychiatry 2014, Advance online publication 22 April.
39. Wang G., Han T., Nijhawan D., Theodoropoulos P., Naidoo J., Yadavalli S., Mirzaei H., Pieper A.A., Ready J.M., McKnight S.L. P7C3 Neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014, 158:1324-1334.
40. Wojtowicz J.M., Kee N. BrdU assay for neurogenesis in rodents. Nat. Protoc. 2006, 1:1399-1405.